Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.33, read 2026-11-05
Ethical passes the values gate
Price399.81 USD
Fair value334.82
Ethical score85.8/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-09-17Read Accumulation336.94+18.7% to today ✓Markdown gives way to Accumulation first Accumulation read since July
2026-08-18Read Markdown351.02+13.9% to today Accumulation gives way to Markdown after a 12% rise in 7 weeks
2026-07-02Read Accumulation314.50+27.1% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
West Pharmaceutical Services holds its Accumulation at $399.81. Consolidating, no directional conviction, held for 64 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 64 days
Price at the screen
$399.81
Valuation
52.83 trailing · 41.33 forward price to earnings
Values screen
PASS· score 85.8
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.52%
Below 33%
Interest-bearing debt is just 7.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.97%
Below 33%
Cash held in interest-bearing accounts and securities is 5.0% of assets, under the one-third limit.
Pass
Receivables
31.98%
Below 49%
Money owed to the company is 32.0% of assets, under the 49% limit.
Pass
Revenue purity
0.57%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
West Pharmaceutical Services clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when WST's ethical verdict changes
Today WST passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $334.82 fair value estimate, moderate competitive moat, 8.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 19.4% above the base estimate.
Third-party analyst targets: 15 covering, consensus Strong Buy. The average target sits +13% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $334.82, with a range of $306.00 to $385.05, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The quiet supplier behind every safe injection
Every time a biologic reaches a patient, it travels inside packaging that must not fail. West Pharmaceutical Services builds those vials and delivery systems across the Americas, Europe and Asia, posting 21% revenue growth, 17% profit margins and 19% ROE.
Those results are respectable, yet the shares sit 16% above our fair value at a 37 times forward earnings multiple. The market is already paying for strong growth that may not repeat at the same pace, leaving the stock overvalued on plain numbers.
A moderate moat and clean ethical screen reduce some concerns, but high valuation still leaves investors exposed if drug spending slows or input costs rise. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
WST trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$408.78+1.3%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. Since the last review it entered the Titan Ethical 500.
2026-10-29Accumulation$403.64+5.1%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$384.02+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$384.02+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$384.02+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$384.02+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$384.02+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$384.02+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$384.02+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$384.02+4.9%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
